{"id":"W2891078672","doi":"10.1038/s41416-018-0164-0","title":"Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma","year":2018,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Exelixis; Memorial Sloan-Kettering Cancer Center","keywords":"Cabozantinib; Pazopanib; Sunitinib; Medicine; Everolimus; Renal cell carcinoma; Internal medicine; Oncology; Urology; Progression-free survival; Tyrosine-kinase inhibitor; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006788173,0.0001781829,0.0006453918,0.0002395989,0.0000367764,0.00002003943,0.0002093429,0.00007650792,0.0002266295],"category_scores_gemma":[0.0001489623,0.0001295377,0.0002663952,0.000298137,0.0001058397,0.00009130653,0.00001037193,0.0003624244,0.000002333164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002181341,"about_ca_system_score_gemma":0.0004984277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00067993,"about_ca_topic_score_gemma":0.0009188331,"domain_scores_codex":[0.9978261,0.00022451,0.0007616211,0.000193761,0.0007153061,0.0002787172],"domain_scores_gemma":[0.9986214,0.0003152044,0.0004746306,0.000242459,0.0002496854,0.00009662874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5613578,0.004722101,0.04562785,0.00007166932,0.0001587917,0.004353505,0.0007798155,0.0001576194,0.01041165,0.000003841135,0.0007838599,0.3715715],"study_design_scores_gemma":[0.5065209,0.02352422,0.4128005,0.0004973053,0.0001455353,0.0001587308,0.0001913708,0.00006388543,0.05259061,0.000009198165,0.003333722,0.0001640388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932787,0.00339322,0.000005159188,0.0004948176,0.0006389865,0.0007544935,0.00002586579,0.000003421417,0.001405314],"genre_scores_gemma":[0.9981695,0.0005889072,0.0003069763,0.0003857862,0.0004107539,0.00003748567,0.000003396161,0.00002433271,0.00007289983],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3714074,"threshold_uncertainty_score":0.5282394,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03876065357668174,"score_gpt":0.3488410741432547,"score_spread":0.3100804205665729,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}